Meta-analysis of the value of serum CEA, CA153, and CA125 tests in opportunistic screening for breast cancer in Chinese population
10.3760/cma.j.cn115624-20231204-00320
- VernacularTitle:血清CEA、CA153和CA125检测在中国人群乳腺癌机会性筛查中应用的荟萃分析
- Author:
Xiao MA
1
;
Nianchang WANG
;
Jian YIN
;
Qiutong WANG
Author Information
1. 中日友好医院健康体检中心，北京 100029
- Keywords:
Breast neoplasms;
Tumor markers;
Diagnostic tests;
Meta-analysis
- From:
Chinese Journal of Health Management
2024;18(4):263-270
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the value of serum carcinoembryonic antigen (CEA), glycan antigen 153 (CA153) and CA125 tests in opportunistic screening of breast cancer in a Chinese population with meta-analysis.Methods:The published literatures of opportunistic screening of breast cancer was searched in the databases of China Knowledge Network database, Wanfang database, WIP Chinese Science and Technology Journal Full Text Database, PubMed, Embase, and Cochrane Library were retrieved from the establishment of the databases to May 2023. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) scale was used for quality assessment. The software of Stata 17.0 and RevMan were used for data analysis.Results:A total of 21 studies with a total of 4 583 cases were included. In diagnosis of breast cancer, the sensitivity with CEA was 0.28 (95% CI: 0.23-0.33), and the specificity was 0.98 (95% CI: 0.94-0.99); the sensitivity with CA153 was 0.48 (95% CI: 0.41-0.55) and the specificity was 0.96 (95% CI: 0.94-0.98); the sensitivity with CA125 was 0.31 (95% CI: 0.24-0.39) and specificity was 0.97 (95% CI: 0.94-0.98); the sensitivity of the combined test for the three was 0.76 (95% CI: 0.69-0.81), the specificity was 0.93 (95% CI: 0.91-0.94), and the area under the summary receiver operating characteristic (SROC) curve was 0.94 (95% CI: 0.91-0.95). Conclusion:The combination of serum CEA, CA125, and CA153 tests can improve the diagnostic accuracy of breast cancer to a certain extent, but there is insufficient evidence for its application in opportunistic breast cancer screening in population.
